Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line bortezomib + rituximab + ibrutinib for treatment-naive Waldenström macroglobulinemia
2017-004362-95Phase 2Active
- Sponsor
- University Hospital Ulm
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib, rituximab and ibrutinib in Waldenström macroglobulinemia (WM), sponsored by University Hospital Ulm. Primary endpoint: 1-year progression-free survival rate. Started Feb 2019; status: active.
02
Drugs
bortezomibrituximabibrutinib
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on 2017-004362-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004362-95.